NYSEMKT: CLDICalidi Biotherapeutics Inc Stock Ownership - Who owns Calidi Biotherapeutics?
Insider buying vs selling
Have Calidi Biotherapeutics Inc insiders been buying or selling?
Buy
Sell
| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| James A. Schoeneck | Director | 2024-04-18 | 375,000 | $0.40 | $150.00kBuy |
| Scott Leftwich | Director | 2023-12-21 | 8,958 | $1.80 | $16.12kBuy |
| James A. Schoeneck | Director | 2023-12-21 | 10,625 | $1.80 | $19.13kBuy |
| Alan R. Stewart | Director | 2023-12-21 | 7,282 | $1.80 | $13.11kBuy |
| Thomas A. Vecchiolla | Director | 2023-12-21 | 7,709 | $1.80 | $13.88kBuy |
| Alfonso G. Zulueta | Director | 2023-12-21 | 5,644 | $1.80 | $10.16kBuy |
| Hudson Bay Capital Management LP | 10% Owner | 2023-09-12 | 500,000 | $10.49 | $5.25MSell |
CLDI insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership
Be the first to know when CLDI insiders and whales buy or sell their stock.
CLDI Shareholders
What type of owners hold Calidi Biotherapeutics Inc stock?
Institutional
Insider
Retail
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Allan Camaisa | 25.23% | 8,964,521 | $1.42M | Insider |
| Scott Leftwich | 6.72% | 2,387,546 | $377.23k | Insider |
| First Light Acquisition Group LLC | 5.44% | 1,931,852 | $305.23k | Insider |
| Polar Asset Management Partners Inc | 2.43% | 861,800 | $136.16k | Insider |
| Thomas A. Vecchiolla | 1.99% | 708,792 | $111.99k | Insider |
| Cable Car Capital LLC | 1.52% | 538,860 | $85.14k | Institution |
| Stephen Thesing | 1.33% | 471,544 | $74.50k | Insider |
| James A. Schoeneck | 1.25% | 443,759 | $70.11k | Insider |
| Boris Radoslavov Minev | 1.19% | 424,458 | $67.06k | Insider |
| Santidrian Antonio Fernandez | 0.92% | 327,788 | $51.79k | Insider |
CLDI vs Biotech Stocks
Calidi Biotherapeutics Stock Ownership FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.